A previous network meta-analysis of hazard ratios for PFS and ORR found that for patients with advanced breast cancer carrying germline BRCA variants, treatment with PARP inhibitor plus platinum were ideal regimens (16). This evidence concerns the gene PARP1 and breast carcinoma.